In addition, XCL1 expression is related to the number of tumor-infiltrating CD8+ T-cells and PD-L1 expression on ovarian tumor cells, which indicated that XCL1 might be a biomarker for anti-PD1/PD-L1 immunotherapy (Tamura et al., 2020). Here, CD8A is linked to neoplasm.